Company intelligence / Profile preview
Attune Pharmaceuticals
New York, New York, United Statesattunepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Attune Pharmaceuticals has completed Phase 1 trials for ATN-249, their lead candidate for HAE treatment, demonstrating safety, tolerability, and pharmacodynamic profile. The company raised $23 million in Series B financing to advance ATN-249 through Phase 2 trials.
- Therapeutic areas
- ImmunologyRare Diseases
- Modalities
- Small moleculesOrally-administered therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Attune Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Attune Pharmaceuticals.